| Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal dystrophies: report of the guideline development subcommittee of the American Academy of … P Narayanaswami, M Weiss, D Selcen, W David, E Raynor, G Carter, ... Neurology 83 (16), 1453-1463, 2014 | 218 | 2014 |
| Limb-girdle muscular dystrophy in the United States SA Moore, CJ Shilling, S Westra, C Wall, MP Wicklund, C Stolle, ... Journal of Neuropathology & Experimental Neurology 65 (10), 995-1003, 2006 | 201 | 2006 |
| Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients BRR Nallamilli, S Chakravorty, A Kesari, A Tanner, A Ankala, T Schneider, ... Annals of clinical and translational neurology 5 (12), 1574-1587, 2018 | 150 | 2018 |
| A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis M Pasnoor, J He, L Herbelin, TM Burns, S Nations, V Bril, AK Wang, ... Neurology 87 (1), 57-64, 2016 | 129 | 2016 |
| The limb-girdle muscular dystrophies MP Wicklund, JT Kissel Neurologic clinics 32 (3), 729-749, 2014 | 100 | 2014 |
| The muscular dystrophies MP Wicklund CONTINUUM: Lifelong Learning in Neurology 19 (6), 1535-1570, 2013 | 79 | 2013 |
| Developing standardized corticosteroid treatment for Duchenne muscular dystrophy M Guglieri, K Bushby, MP McDermott, KA Hart, R Tawil, WB Martens, ... Contemporary clinical trials 58, 34-39, 2017 | 72 | 2017 |
| Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy: a randomized clinical trial M Guglieri, K Bushby, MP McDermott, KA Hart, R Tawil, WB Martens, ... Jama 327 (15), 1456-1468, 2022 | 71 | 2022 |
| Amyotrophic lateral sclerosis: what role does environment play? A Ahmed, MP Wicklund Neurologic clinics 29 (3), 689-711, 2011 | 61 | 2011 |
| Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis Q Gang, C Bettencourt, PM Machado, S Brady, JL Holton, AM Pittman, ... Neurobiology of aging 47, 218. e1-218. e9, 2016 | 54 | 2016 |
| SCN4A mutation as modifying factor of myotonic dystrophy type 2 phenotype E Bugiardini, I Rivolta, A Binda, AS Caminero, F Cirillo, A Cinti, ... Neuromuscular disorders 25 (4), 301-307, 2015 | 52 | 2015 |
| Novel clinical features of glycine receptor antibody syndrome: a series of 17 cases AL Piquet, M Khan, JEA Warner, MP Wicklund, JL Bennett, MA Leehey, ... Neurology: Neuroimmunology & Neuroinflammation 6 (5), e592, 2019 | 50 | 2019 |
| Spinal angiography and epidural venography in juvenile muscular atrophy of the distal arm “Hirayama disease” B Elsheikh, JT Kissel, G Christoforidis, M Wicklund, DT Kehagias, ... Muscle & Nerve: Official Journal of the American Association of …, 2009 | 49 | 2009 |
| The limb-girdle muscular dystrophies MP Wicklund CONTINUUM: Lifelong Learning in Neurology 25 (6), 1599-1618, 2019 | 48 | 2019 |
| Paraproteinemic neuropathy MP Wicklund, JT Kissel Current Treatment Options in Neurology 3, 147-156, 2001 | 44 | 2001 |
| A checklist for clinical trials in rare disease: obstacles and anticipatory actions—lessons learned from the FOR-DMD trial RA Crow, KA Hart, MP McDermott, R Tawil, WB Martens, BE Herr, ... Trials 19, 1-9, 2018 | 36 | 2018 |
| Amyotrophic lateral sclerosis: possible role of environmental influences MP Wicklund Neurologic clinics 23 (2), 461-484, 2005 | 35 | 2005 |
| KIF1Bβ mutations detected in hereditary neuropathy impair IGF1R transport and axon growth F Xu, H Takahashi, Y Tanaka, S Ichinose, S Niwa, MP Wicklund, ... Journal of Cell Biology 217 (10), 3480-3496, 2018 | 30 | 2018 |
| Patient assisted intervention for neuropathy: comparison of treatment in real life situations (PAIN-CONTRoLS): Bayesian adaptive comparative effectiveness randomized trial RJ Barohn, B Gajewski, M Pasnoor, A Brown, LL Herbelin, KS Kimminau, ... JAMA neurology 78 (1), 68-76, 2021 | 29 | 2021 |
| Guideline Development Subcommittee of the American Academy of Neurology P Narayanaswami, M Weiss, D Selcen, W David, E Raynor, G Carter, ... | 27 | 2014 |
